Nuvo Pharmaceuticals Inc (TSE:NRI) Downgraded by Bloom Burton

Bloom Burton downgraded shares of Nuvo Pharmaceuticals Inc (TSE:NRI) from a buy rating to an accumulate rating in a research report sent to investors on Friday, November 3rd.

Shares of Nuvo Pharmaceuticals (TSE NRI) opened at C$3.83 on Friday. Nuvo Pharmaceuticals has a one year low of C$3.64 and a one year high of C$6.43.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://weekherald.com/2017/11/15/bloom-burton-lowers-nuvo-pharmaceuticals-inc-nri-to-accumulate.html.

Nuvo Pharmaceuticals Company Profile

Nuvo Pharmaceuticals Inc, formerly Nuvo Research Inc, is a Canada-based healthcare company. The Company offers a range of commercial products, including Pennsaid 2%, Pennsaid and the heated lidocaine/tetracaine (HLT) patch. The Company’s Pennsaid 2% is a non-steroidal anti-inflammatory drug (NSAID) containing 2% diclofenac sodium.

Receive News & Ratings for Nuvo Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvo Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply